HK1087638A1 - Use of tyrosine kinase inhibitors to treat diabetes - Google Patents

Use of tyrosine kinase inhibitors to treat diabetes

Info

Publication number
HK1087638A1
HK1087638A1 HK06107985.6A HK06107985A HK1087638A1 HK 1087638 A1 HK1087638 A1 HK 1087638A1 HK 06107985 A HK06107985 A HK 06107985A HK 1087638 A1 HK1087638 A1 HK 1087638A1
Authority
HK
Hong Kong
Prior art keywords
tyrosine kinase
kinase inhibitors
diabetes
treat diabetes
type
Prior art date
Application number
HK06107985.6A
Other languages
English (en)
Inventor
Robert P Haegerkvist
Nils Richard Welsh
Original Assignee
Robert P Haegerkvist
Nils Richard Welsh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312086A external-priority patent/GB0312086D0/en
Priority claimed from GB0402682A external-priority patent/GB0402682D0/en
Application filed by Robert P Haegerkvist, Nils Richard Welsh filed Critical Robert P Haegerkvist
Publication of HK1087638A1 publication Critical patent/HK1087638A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK06107985.6A 2003-05-27 2006-07-17 Use of tyrosine kinase inhibitors to treat diabetes HK1087638A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0312086A GB0312086D0 (en) 2003-05-27 2003-05-27 Organic compounds
GB0402682A GB0402682D0 (en) 2004-02-06 2004-02-06 Organic compounds
PCT/EP2004/005679 WO2004105763A2 (en) 2003-05-27 2004-05-26 Use of tyrosine kinase inhibitor to treat diabetes

Publications (1)

Publication Number Publication Date
HK1087638A1 true HK1087638A1 (en) 2006-10-20

Family

ID=33492240

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06107985.6A HK1087638A1 (en) 2003-05-27 2006-07-17 Use of tyrosine kinase inhibitors to treat diabetes

Country Status (21)

Country Link
US (1) US7875616B2 (xx)
EP (1) EP1631291B1 (xx)
JP (1) JP4776537B2 (xx)
KR (1) KR101102229B1 (xx)
AT (1) ATE439133T1 (xx)
BR (1) BRPI0410704A (xx)
CA (1) CA2526594C (xx)
DE (1) DE602004022540D1 (xx)
DK (1) DK1631291T3 (xx)
ES (1) ES2331800T3 (xx)
HK (1) HK1087638A1 (xx)
IL (1) IL171927A (xx)
IS (1) IS2712B (xx)
MA (1) MA27812A1 (xx)
MX (1) MXPA05012739A (xx)
NO (1) NO331715B1 (xx)
NZ (1) NZ543709A (xx)
PL (1) PL1631291T3 (xx)
PT (1) PT1631291E (xx)
RU (1) RU2365373C2 (xx)
WO (1) WO2004105763A2 (xx)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016323A2 (en) * 2003-08-15 2005-02-24 Ab Science Use of c-kit inhibitors for treating type ii diabetes
US20060094682A1 (en) * 2004-10-29 2006-05-04 Odyssey Thera, Inc. Kinase inhibitors for the treatment of diabetes and obesity
CN101484427A (zh) * 2006-06-30 2009-07-15 协和发酵麒麟株式会社 Abl激酶抑制剂
JP2014526506A (ja) * 2011-09-15 2014-10-06 ノバルティス アーゲー 中等度肝障害患者の癌治療における４−アミノ−５−フルオロ−３−［６−（４−メチルピペラジン−１−イル）−１ｈ−ベンゾイミダゾール−２−イル］−１ｈ−キノリン−２−オンの使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (xx) * 1992-04-03 1994-06-21 Ciba Geigy Ag
EP0773313B1 (de) * 1995-10-11 2000-08-09 ARTEVA TECHNOLOGIES S.à.r.l. Schwerentflammbare Sicherheitsgurte enthaltend phosphor-modifizierte Polyesterfasern
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
ATE289586T1 (de) * 1999-03-01 2005-03-15 Pfizer Prod Inc Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor
SK12992002A3 (sk) * 2000-02-15 2003-05-02 Teva Pharmaceutical Industries Ltd. Spôsob syntézy leflunomidu
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
MY128449A (en) * 2000-05-24 2007-02-28 Sugen Inc Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
PE20020776A1 (es) * 2000-12-20 2002-08-22 Sugen Inc Indolinonas 4-aril sustituidas
AU2002334355A1 (en) * 2001-09-06 2003-03-18 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
AUPS243002A0 (en) 2002-05-20 2002-06-13 Baker Medical Research Institute Therapeutic target and uses thereof
DE10235227A1 (de) * 2002-08-01 2004-02-19 Johann Berger Verfahren zur Herstellung eines gewebten Gurtbandes
EP1576129A4 (en) 2002-08-09 2008-01-23 Theravance Inc ONCOKINASE FUSION POLYPEPTIDES ASSOCIATED WITH HYPERPROLIFERATIVE DISORDERS, NUCLEIC ACIDS ENCODING THESE POLYPEPTIDES AND METHODS OF DETECTION AND IDENTIFICATION THEREOF
WO2004043408A2 (en) 2002-11-13 2004-05-27 Genpath Pharmaceuticals, Incorporated Gpc15: methods and compositions for treating cancer
DE10255360A1 (de) * 2002-11-27 2004-06-17 Johann Berger Verfahren zur Herstellung eines gewebten Gurtbandes

Also Published As

Publication number Publication date
BRPI0410704A (pt) 2006-06-13
ATE439133T1 (de) 2009-08-15
ES2331800T3 (es) 2010-01-15
KR20060021865A (ko) 2006-03-08
MA27812A1 (fr) 2006-03-01
IL171927A (en) 2011-10-31
NZ543709A (en) 2009-04-30
CA2526594A1 (en) 2004-12-09
NO20056188L (no) 2005-12-23
WO2004105763A2 (en) 2004-12-09
AU2004243491A1 (en) 2004-12-09
DE602004022540D1 (de) 2009-09-24
PL1631291T3 (pl) 2010-04-30
NO331715B1 (no) 2012-03-05
EP1631291B1 (en) 2009-08-12
DK1631291T3 (da) 2009-11-02
PT1631291E (pt) 2009-10-28
RU2365373C2 (ru) 2009-08-27
KR101102229B1 (ko) 2012-01-05
CA2526594C (en) 2011-11-08
JP2006528225A (ja) 2006-12-14
US20070072932A1 (en) 2007-03-29
WO2004105763A3 (en) 2005-06-02
JP4776537B2 (ja) 2011-09-21
IS2712B (is) 2011-01-15
IS8139A (is) 2005-11-22
EP1631291A2 (en) 2006-03-08
US7875616B2 (en) 2011-01-25
IL171927A0 (en) 2006-04-10
MXPA05012739A (es) 2006-05-17
RU2005140516A (ru) 2007-07-10

Similar Documents

Publication Publication Date Title
ATE321556T1 (de) Behandlung gastrointestinaler stroma-tumoren
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
MY129772A (en) Crystal modification of a n-phenyl- 2 - pyrimidineamine derivative, processes for its manufacture and its use
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
BR0312873A (pt) 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il) pirimidin-2-ilamino)fenil] benzamida para tratamento de doenças associadas com ret cinase mutante
ES2421587T3 (es) Uso de derivados de pirimidilaminobenzamida para el tratamiento de mastocitosis sistémica
HK1087638A1 (en) Use of tyrosine kinase inhibitors to treat diabetes
DE602007011756D1 (de) Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen
BR0316126A (pt) Combinação de compostos para o tratamento de leucemia linfocìtica crÈnica
DE60321888D1 (xx)
TNSN05304A1 (en) Use of tyrosine kinase inhibitor to treat diabetes
WO2006012958A3 (en) Combination comprising a bcrp inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
DE602005025514D1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n-4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl-benzamid zur hemmung des tyrosinkinaserezeptors c-fms
WO2004026930A3 (en) The method for reducing inflammation using sti-571 or its salt
DE60305460D1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen
NZ610401A (en) Inhibitors of the mutant form of kit
TN2011000037A1 (en) Treatment of pulmonary arterial hypertension

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150526